文献速递术前评估与围术期医学气道管理

胰高血糖素样肽-1受体激动剂围术期应用:为麻醉科医生厘清误区与关键考量

Glucagon-like peptide-1 receptor agonists in peri-operative care: Dispelling myths and unveiling insights with essential considerations for anaesthesiologists.
PubMed 文献 · Eur J Anaesthesiol · 2024-11-29

随着GLP-1受体激动剂作为抗肥胖药物使用日益增多,其围术期影响亟需审视。该文汇总现有证据与指南,指出虽推测胃轻瘫增加,但尚无研究证实肺误吸风险升高,未来应聚焦误吸实际风险及术前超声评估。

要点

  • GLP-1受体激动剂可致胃轻瘫,引发麻醉诱导肺误吸的安全顾虑。
  • 现有证据尚无法证实肺误吸风险确实升高。
  • 未来需研究误吸实际风险并探索术前超声评估。

核心结论

  • 当前证据提示GLP-1受体激动剂使用者胃轻瘫可能增加,但尚无研究证实肺误吸风险升高。

研究设计与样本

  • 本文为综述,汇总GLP-1受体激动剂围术期相关现有证据及已建立指南。

主要发现

  • 现有证据使人假设胃轻瘫确实增加,但至今无研究以证据确认推测的肺误吸风险升高。

临床怎么用

  • 麻醉科医生应关注GLP-1受体激动剂使用者的胃轻瘫与肺误吸风险,并参考现有指南。

局限性

  • 尚无研究以证据确认肺误吸风险升高,未来需聚焦误吸实际风险及术前超声评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the growing use of glucagon-like-peptide-1 (GLP-1) receptor (GLP-1R) agonists as anti-obesity medication it is becoming increasingly important to examine its consequences in the peri-operative period. GLP-1R agonists are known for their effects of glucose-lowering and gastroparesis the latter causing some safety concerns regarding induction of anaesthesia, more specifically the risk of pulmonary aspiration. This article gathers the available evidence on this subject in addition to the already established guidelines. Current evidence makes us assume there is indeed an increased level of gastroparesis, but there are no studies to date with evidential confirmation of a presumed elevated risk of pulmonary aspiration. Future perspectives should focus on the actual risk of pulmonary aspiration and the possible implementation of ultrasound in the preoperative assessment.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Paggers L, Mesotten D, Stragier H, et al. Glucagon-like peptide-1 receptor agonists in peri-operative care: Dispelling myths and unveiling insights with essential considerations for anaesthesiologists. Eur J Anaesthesiol. 2024. PMID: 39620622. doi:10.1097/EJA.0000000000002103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。